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Abstract
Large-scale production of biopharmaceuticals by current bioreactor techniques is limited by low transgenic efficiency and
low expression of foreign proteins. In general, a bacterial artificial chromosome (BAC) harboring most regulatory elements is
capable of overcoming the limitations, but transferring BAC into donor cells is difficult. We describe here the use of cattle
mammary bioreactor to produce functional recombinant human lactoferrin (rhLF) by a novel procedure of transgenic
cloning, which employs microinjection to generate transgenic somatic cells as donor cells. Bovine fibroblast cells were co-
microinjected for the first time with a 150-kb BAC carrying the human lactoferrin gene and a marker gene. The resulting
transfection efficiency of up to 15.79610
22 percent was notably higher than that of electroporation and lipofection.
Following somatic cell nuclear transfer, we obtained two transgenic cows that secreted rhLF at high levels, 2.5 g/l and 3.4 g/
l, respectively. The rhLF had a similar pattern of glycosylation and proteolytic susceptibility as the natural human
counterpart. Biochemical analysis revealed that the iron-binding and releasing properties of rhLF were identical to that of
native hLF. Importantly, an antibacterial experiment further demonstrated that rhLF was functional. Our results indicate that
co-microinjection with a BAC and a marker gene into donor cells for somatic cell cloning indeed improves transgenic
efficiency. Moreover, the cattle mammary bioreactors generated with this novel procedure produce functional rhLF on an
industrial scale.
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Introduction
Human lactoferrin (hLF) is a multifunctional glycoprotein of
80 kDa secreted in many tissue fluids including tears, saliva,
semen, vaginal secretion, milk, and plasma[1]. Both in vitro and in
vivo evidence indicate that hLF is involved in iron absorption in the
intestinal tract [2] as well as in broad-spectrum primary defense
against bacteria [3], fungi [4], protozoa [5] and viruses [6]. In
addition, several studies also suggest that hLF modulates the
inflammatory response [7], regulates gene expression [8], and
promotes bone growth [9]. These bioactivities suggest that hLF
may have important therapeutic applications, such as in
prophylaxis treatment, nutritional supplementation, and food
and/or medicine preservation. Therefore, market demand for
hLF is primed to expand dramatically. A number of attempts have
been made to produce recombinant human lactoferrin (rhLF)
using prokaryotic and eukaryotic expression systems [10–16].
However, problems such as low protein expression level, lack of
accurate post-translational modifications as well as complex
purification procedures have made current approaches unsuitable
for large-scale production. Recently, transgenic mice expressing
rhLF were successfully established by Platenburg’s group, which
paved the way for harvesting rhLF by means of a mammary
bioreactor [17,18]. As such, a cattle mammary bioreactor would
be an excellent system for large-scale production of rhLF because
of its established faithful incorporation of post-translational
modifications and efficiency for purification of heterologous
proteins.
To date, more than ten recombinant proteins have been
produced in the milk of either goats, sheeps, rabbits or pigs [19].
Furthermore, several functional heterologous proteins, including
lysostaphin [20], bovine casein [21] and hLF [22], have been
produced via cattle mammary bioreactors. Although a cattle
mammary bioreactor secreting functional rhLF at 2.8 mg/ml has
been established [22], its low transgenic efficiency is attributable to
the pronuclear microinjection technique used and the extensive
waiting period required to establish the transgenic animals lines
[23]. However, a combination of gene transfer in cultured somatic
cells and somatic cell nuclear transfer techniques provide an
attractive alternative to improve the transgenic efficiency. We thus
employed this approach to produce large amounts of biologically
active rhLF in the cattle mammary bioreactor. For high-level and
stable expression of rhLF in transgenic animals, we had previously
optimized the use of a construct carrying the entire hLF genomic
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at up to 8 mg/ml of milk [24]. Our results demonstrated that
expression of rhLF by a bacterial artificial chromosome (BAC)
containing the entire hLF genomic sequence is an effective means
for the generation of transgenic animals capable of expressing
high-levels of stable protein. However, because of its large size, a
BAC is not easy to transfer into cells by conventional techniques.
Microinjection is an effective technique for the introduction of
large DNA fragments into cell nuclei but, to our knowledge, there
have been no reports on the microinjection of a BAC into cultured
cells to produce a livestock mammary bioreactor. Therefore, we
pursued this goal by co-microinjecting a 150-kb BAC containing
the entire hLF gene (including 90-kb and 30-kb 59 and 39 flanking
regions) with a plasmid encoding a marker gene into bovine fetal
fibroblast cells. With subsequent transgenic cloning, we obtained
transgenic cattle that expressed a high-level of functional rhLF.
Results
Transfection of hLF BAC DNA
The hLF BAC was successfully integrated into bovine fibroblast
cells by microinjection, with integration efficiencies of up to
15.79610
22 percent (table 1). In our experiments, both electro-
poration and lipofection were unable to transfect the hLF BAC
into cells (data not shown). It was also noted that the integration
efficiency of plasmid pCEIN containing two marker genes, by
microinjection was apparently higher than by either electropora-
tion or lipofection (data not shown).
Production of transgenic cattle
Of 623 reconstructed embryos, 280 developed to blastocysts.
Among these, 98 randomly chosen blastocysts were transferred to
50 recipient cows (table 2). Ten cows became pregnant after
embryo transfer, and five calves were born at full term (the others
were spontaneously aborted). Finally, two calves, named 211 and
Xiang, survived after weaning and both were apparently healthy.
Three out of five calves died of gastrointestinal disease after birth.
It is well established that some unknown mechanisms affect the
development, growth and/or survival of cloned animals [25,26].
Though neonatal losses are common in cloning and decrease the
overall success rate, the surviving calves are almost always
transgenic.
Identification of the rhLF transgene in cattle
PCR results indicated that the 150-kb whole-genomic hLF
sequence was introduced intact into the bovine genome
(Figure 1A). Southern blotting confirmed the PCR results and
showed that 211 and Xiang received one and two copies of the
transgene, respectively (Figure 1B). Western blotting indicated that
these two cows were likely to produce rhLF at high levels
(Figure 1C). Analysis by radioimmunoassay (RIA) further
demonstrated that rhLF was highly expressed in the transgenic
milk, at concentrations of 2.560.2 g/l (211) and 3.460.4 g/l
(Xiang). Fluorenscent in situ hybridization (FISH) analysis revealed
that the BAC integrated into a single location in the genome of
cattle (Figure S1).
Composition analysis of transgenic milk
The gross composition of the transgenic milk, including fat, total
protein, lactose and dry matter, was similar to that of non-
transgenic milk (Figure 2A). Furthermore, the total protein profiles
of whole milk from transgenic cattle, EGFP-NEO-transgenic
cattle, cloned cattle, and non-transgenic cattle also were similar,
with the exception of high-level expression of rhLF in transgenic
milk (Figure 2B). Moreover, two-dimensional electrophoresis
showed no obvious differences in the major milk proteins between
transgenic milk and normal milk (Figure 2C). However protein B
was detected in transgenic milk, whereas protein A was detected in
normal milk. The two proteins had different isoelectric points. The
results of peptide mass fingerprint showed that proteins A and B
were b-lactoglobulin a and b-lactoglobulin b, respectively, which
are constitutive components of normal milk (Figure S2C).
Purification of rhLF from milk of transgenic cows
hLF contains many basic residues, and thus we used cation-
exchange chromatography to purify rhLF. Two proteins, labeled
P1 and P2, were eluted at 0.70 M and 0.60 M NaCl concentra-
tion, respectively (Figure 3A). Western blotting indicated that P1
Table 1. Efficiency of co-transfection of hLF BAC and pCEIN by microinjection.
Manipulated cells GFP and Neo
r positive colonies* hLF BAC integration colonies
{
Number Efficiency(%) Number Efficiency(%)
2050 21 1.02 2 9.76610
22
2300 17 0.74 2 8.70610
22
1900 18 0.95 3 15.79610
22
*After approximately 20 days, the positive colonies (expressing GFP and Neo
r) were screened by G418 and confirmed by the expression of GFP.
{After the GFP and Neo
r positive colonies were selected and expanded, DNA extraction was performed using some cells from each colony, and the integrated cells were
determined by PCR using primer P1, P2 and P3.
doi:10.1371/journal.pone.0003453.t001
Table 2. Efficiency of steps in cloned process from oocytes to
transgenic calves.
Step Total No. Percent*
Oocytes 844 –
Re-constructed embryos 623/844 73.8
Blastocysts 280/623 44.9
Transferred recipients 50/98
{ 51.0
Pregnant 10/50 20.0
Born alive 5/10 50.0
Alive after weaning 2/98 2.04
*Percent indicate the percentage of embryos obtained successfully each step.
{96 blastocysts were transferred to 48 recipients with two blastocysts per
recipient and 2 blastocysts were transferred to 2 recipients with one blastocyst
per recipient.
doi:10.1371/journal.pone.0003453.t002
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by peptide mass fingerprinting (Figure S2A) and N-terminal
sequencing (Figure 3A). Furthermore, the efficiency of rhLF
recovery from whole milk was 76%, as determined by ELISA (data
not shown).
Biochemical properties of rhLF
SDS-PAGE analysis of purified rhLF indicated that its apparent
mass was slightly lower than that of hLF (Figure 3B). However,
there was no difference in Mr after treatment with PNGase F
(Figure 3C). Still, some differences were detected when the
recombinant protein was treated with Endo H (Figure 3C). These
differences may likely be caused by small variations in glycosyl-
ation patterns between rhLF and hLF; likely attributable to the
slight difference in Mr. The Mr of glycosylated rhLF obtained by
MALDI-TOF was 79,494620 Da (Figure S2B). Hence, the Mr of
glycans of rhLF was estimated to be about 3 kDa by comparing
the Mr of rhLF (the theoretical value of unglycosylated hLF is
76,320 Da).
Susceptibility of rhLF to proteolysis
hLF is relatively resistant to degradation by trypsin, and this
resistance to trypsin proteolysis is dependent on the extent/type of
glycosylation on hLF [27]. Thus, we studied the susceptibility of
glycosylated and unglycosylated forms rhLF to proteolysis by
trypsin. Both unglycosylated rhLF and hLF were completely
digested after treatment of 15 min (Figure 4A). We also studied
susceptibility of rhLF to pepsin; both unglycosylated and
glycosylated rhLF and hLF were completely proteolyzed after
treatment of 1 h (Figure 4B).
Iron binding and releasing properties of rhLF
One mole LF can bind two moles of metal ions accompanied by
two moles of carbonate [1]. The absorbance spectrum at 465 nm
of saturated LF is clearly altered from that of unliganded LF,
indicating that LF binds to iron [13]. We analyzed the iron
binding properties of rhLF and compared them with native hLF.
The absorption peak of unliganded rhLF at 465 nm was clearly
shifted after incubation with FeNTA solution for 1 hour
(Figure 5A), suggesting that rhLF could bind iron. Iron can be
released from the iron-saturated LF in acidic conditions [1]. We,
therefore, studied the iron releasing properties of rhLF by
incubating iron-liganded rhLF in solutions of varying pH. Iron
release from rhLF was similar to that of hLF, and the release
began to occur at ,pH 4.5 and was complete at ,pH 2.0
(Figure 5B). Iron-free LF had greater electrophoretic mobility on
SDS-PAGE compared with iron-bound LF, apparently due to
changes in tertiary structure (data not shown).
Antibacterial effect of rhLF in vitro
The ability of hLF to suppress bacterial proliferation is one of its
most important properties; and thus, we tested rhLF for its
effectiveness at inhibiting E. coli growth (Figure 6). The presence of
5 mg/ml rhLF significantly slowed E. coli proliferation compared
to untreated controls. The suppressive effect of rhLF on bacterial
growth was similar to that of hLF, and when 2 mg/ml of rhLF or
Figure 1. Results of determination of the hLF transgene. (A) Schematic representation of the transgene. A BAC containing the complete hLF
genomic DNA (,28.9-kb genomic sequence containing human hLF flanked by a 90-kb 59 flanking and a 31-kb 39 flanking region) were microinjected
into bovine fetal fibroblasts. The black box showed the 2.2 kb EcoR I fragment used as probe in Southern blot. The positions of P1, P2 and P3 primers
for PCR screening are indicated by arrows. (B) Southern analysis of DNA from transgenic calves. Genomic DNA (10 mg) was digested by EcoR I and
hybridized by a
32P-labeled fragment. 211 and XIANG, transgenic calves; NC, non-transgenic calf; PC, positive controls with 1, 5 and 10 copies. (C)
Western blot analysis of LF in milk. 211 and XIANG, transgenic milk; PC, human lactoferrin standard; NC, non-transgenic milk.
doi:10.1371/journal.pone.0003453.g001
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hour time point.
Discussion
To our knowledge, this is the first study in which a BAC
containing the hLF gene has been expressed in the cattle
mammary bioreactor. It is well established that additional
regulatory elements may improve the expression of an exogenous
gene, and BACs generally contain all the regulatory elements
necessary for gene expression [28]. Therefore, the use of a BAC to
carry a transgene may be the best alternative for producing stable
recombinant proteins at a high and sustained level. In addition,
the use of a BAC probably diminishes the ‘‘position effect’’—
caused by the chromosomal insertion site of an exogenous gene.
Hence, we chose a 150-kb hLF BAC to carry the hLF transgene
into bovine fetal fibroblasts to generate transgenic cattle. Our
results suggest that the cattle mammary bioreactor is an efficient
means for production of bioactive rhLF on a large scale.
Because of their large size, however, BACs are difficult to
transfer into fibroblast cells by conventional techniques. In this
study, 150 kb hLF BAC was not integrated into bovine fibroblast
cells by electroporation or lipofection which were proved to be
feasible for transfection of large DNA in other’s studies[29–31].
Fortunately, it had already been reported that the microinjection
technique is approximately one thousand times more efficient in
producing gene-expressing cells than the transfection technique
[32]. Furthermore, microinjection has been proven to be an
effective approach for the transfection of plasmids containing
exogenous gene into cells. However, there has been no reports on
microinjection of large DNA fragment, such as BAC, YAC or
PAC, into livestock cells. Zhang et al. reported transfection of YAC
by polyethylene glycol-mediated spheroplast fusion [33]. Unfor-
tunately, the average efficiency of fusion was approximately 36 per
2610
6 fibroblasts. Although many transgenic animals containing
large-size DNA, have been obtained in the past decade, most have
been performed in the mouse. Furthermore, gene transfer was
primarily performed by pronuclear microinjection of large-size
DNA, lipofection into ES cell or cell fusion with ES cell [28,34],
but all above gene transfer methods are notorious for low
transfection efficiencies. We demonstrate, for the first time, the
successful use of microinjection of bovine fibroblasts with a
mixture of hLF BAC and a reporter gene to generate transgenic
cattle. Moreover, the integration efficiency of BAC microinjection
Figure 2. Composition analysis of transgenic milk. (A) Comparison of basic components of transgenic milk with those of conventional milk.
Open bars, milk of 211; gray bars, milk of xiang; black bars, milk of non-transgenic cattle. (B) Analysis of proteins in whole milk via 15% SDS-PAGE.
Whole milk (1.5 ml) of each group was loaded. M, protein marker; hLF, human lactoferrin standard; Human, human milk; Xiang, milk of hLF-transgenic
calf xiang; T genic, milk of EGFP-NEO-transgenic calves; Clone, milk of cloned calves; calf, milk of non-transgenic calves; cow, milk of non-transgenic
cows. (C) Global profiles of proteins expressed in non-transgenic milk (top) and transgenic milk (bottom) via two-dimensional gel electrophoresis.
Total protein (25 mg) was loaded. The double-headed arrows indicate the range of pH. The protein spots labeled A and B correspond to b-
lactoglobulin variant a and b-lactoglobulin variant b, respectively.
doi:10.1371/journal.pone.0003453.g002
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suggests that microinjection provides an effective method for
transfer of large-size DNA into cultured cells.
Although there is neither an official authorization or restrictive
policy in China, the neomycin resistance gene still is extensively
applied in transgenic research as a marker gene. In consideration
of health concerns regarding both transgenic animals and humans,
we investigated the expression of reporter genes in the tissue of the
calves that died post-natal. Interestingly, the expression of the
neomycin resistance gene and EGFP gene used as reporter genes
in this study, were not detected in the heart, liver, spleen, lung,
kidney, skin or muscle of the transgenic cattle as detected by
radioimmunoassay (data not shown).
Although van Berkel et al. [22] reported the production of hLF
transgenic cattle at expression levels of up to 2.8 mg/ml, the
transgenic efficiency of 1.5% (2/129) was very low using
pronuclear injection [23]. To overcome the experimental
limitations of inefficient transgene integration that have long
plagued researchers in the past, we combined the transgenic
technique of microinjection and somatic cell nuclear transfer. The
survived calves were all transgenic. We have, thus, resolved the
problem of low transgenic efficiency by introducing the transgene
into cultured cells followed by subsequent somatic cell nuclear
transfer.
Moreover, animal usage was greatly economized in this study. A
total of 844 oocytes were used and the efficiency of blastocyte
formation was 45% (280/623), whereas the number of oocytes
used in Krimpenfort’s study was 2470 and the efficiency of
blastocyte formation was 11% (129/1154) [23]. In our study, this
is a 66% reduction in total oocytes required and double the
Figure 3. Purification of rhLF by cation exchange chromatography. (A) Profile of purification by liquid chromatography on a HiLoad 16/10 SP
Sepharose HP column. Transgenic milk whey (15 ml) was loaded on the column. The N-terminal sequences of P1 and P2 are shown using the
standard one-letter codes for amino acids. (B) Identification of rhLF by SDS-PAGE (15% gel, top) of SP Sepharose fractions and by western blotting
(bottom). hLF (5 mg) was loaded as a standard. M, protein marker; hLF, human lactoferrin standard; P1 and P2, rhLF eluted from the column; WHEY,
whey of transgenic milk; UB, protein fraction that was not bound to the column. (C) Western blot of rhLF (lanes 1, 3 and 5) and hLF (lanes 2, 4 and 6)
treated with PNGaseF (lanes 1 and 2) or Endo H (lanes 3 and 4) or untreated (lanes 5 and 6). Samples were 5 mg in this experiment.
doi:10.1371/journal.pone.0003453.g003
Figure 4. Proteolytic susceptibility of rhLF. (A) Western blotting
results for rhLF (lanes 1, 2, 5 and 6) and hLF (lanes 3, 4, 7 and 8) treated
with trypsin (lanes 2, 4, 6 and 8) or PNGaseF (lanes 1, 2, 3 and 4). (B)
Western blotting results for rhLF (lanes 1, 2, 5 and 6) and hLF (lanes 3, 4,
7 and 8) treated with pepsin (lanes 2, 4, 6 and 8) or PNGaseF (lanes 1, 2,
3 and 4).
doi:10.1371/journal.pone.0003453.g004
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compared to pronuclear injection, our method is much more
economical for generating transgenic cattle. Because we ensure
that the reconstructed embryos are 100% transgenic before
implantation, fewer recipients are required. To get two transgenic
cows: 50 recipients were used in our study whereas 99 recipients
were used in Krimpenfort’s study, and 147 recipients were used in
Eyestone’s study [35]. Our study used 50% and 66% less
recipients respectively.
As emerging biotechnological tools, the advance of cloning and
transgene techniques provides the basis for an exciting future for
large-scale production of nutrients and pharmaceutical proteins
using the livestock mammary bioreactor. Moreover, previous
studies suggest that the composition of milk and meat products and
the general health of cloned animals are similar to those of non-
transgenic animals [36–38]. Indeed, our comparison of the whole
milk samples of cloned transgenic and natural cattle demonstrated
that the composition of milk from cloned transgenic cows was not
affected by transgene expression or the cloning process utilized in
this study. As such, we anticipate future work will likely confirm
this positive assessment of the quality and safety of transgenic milk.
Many efficient methods, such as ion-exchange chromatography
[39], batch extraction [40] or reversed phase chromatography [41],
have been used successfully to purify LF from milk. However, the
greater the number of steps in the purification, the more product
loss becomes an issue. Therefore, we used a single step of cation
Figure 5. Iron binding and releasing properties of rhLF. (A)
Determination of iron binding of rhLF (top) and hLF (bottom). (B)
Profiles of iron release by rhLF (open bars) and hLF (black bars) as a
function of pH.
doi:10.1371/journal.pone.0003453.g005
Figure 6. Antibacterial effects of rhLF and hLF. Antibacterial
activity of rhLF at 0.5 mg/ml (top), 2 mg/ml (middle) and 5 mg/ml
(bottom) on E. coli growth in liquid culture medium. Dotted bars, rhLF;
gray bars, hLF; open bars, positive control (2 mg/ml ampicillin); black
bars, negative control (nothing added). The experiment for each group
was repeated at least three times, and the results represent means6s.d.
doi:10.1371/journal.pone.0003453.g006
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revealed that p1 and p2, eluted at different NaCl concentrations,
were identified to be rhLF by Western, N-terminal sequencing and
MS analysis. We speculate that a low molecular weight whey
component of negative charge interacts with rhLF in milk, thereby
decreasing the net positive charge of rhLF [39]. Therefore, some of
the rhLF was eluted at relatively lower NaCl concentration.
Comparison of rhLF and hLF on SDS-PAGE revealed a slight
difference in relative Mr of ,2 kDa, probably attributable to the
differences in glycosylation because there was no Mr difference
after deglycosylation. Our previous study revealed that rhLF
expressed in murine milk had three types of glycosylation, at ratio
of 2:3:5 [42]. The type of glycosylation that occurs on a
recombinant protein is basically governed by the host species
and the site of expression [43], and thus the actual molecular mass
of a recombinant glycoprotein may vary from host to host [44–46].
Van Berkel et al. [27] showed that glycans play important roles
in the proteolytic resistance of recombinant proteins. Moreover,
intact hLF has been detected in feces of breast-fed infants [46],
suggesting that hLF is not completely digested in the gastrointes-
tinal tract. Here, we verified that rhLF, similar to native hLF, was
to some extent resistant to proteolysis by trypsin. Unglycosylated
rhLF and hLF were rapidly digested compared with their
glycosylated counterparts. However, the recombinant protein
was likely more susceptible than the native protein; Harri et al. [47]
reported that the greater susceptibility of rhLF to proteolysis is
mainly attributable to the mutations Ile
130-Thr and Gly
404-Cys
rather than glycosylation of hLF. However, a bovine LF variant,
bLF A — glycosylated at Asn
281 — is more resistant to tryptic
proteolysis than bLF B, which is unglycosylated at Asn
281.
Therefore, glycosylation of LF probably plays an important role
in trypsin/proteolytic resistance.
hLF is thought to play a significant role in the transport and
absorption of iron in vivo [48–50] in addition to antibacterial
activities [51]. Therefore, we investigated the iron binding and
releasing properties of rhLF to understand whether the recombi-
nant protein, similar to native protein, chelated iron. In order to
be used as a therapeutic agent, rhLF and hLF would need to have
similar bioactivities, such as bacteriostasis and iron absorption, in
newborns. Our results indicate that rhLF at 5 mg/ml can suppress
bacterial proliferation, whereas at ,2 mg/ml it does not have
adequate bactericidal activity. Recently, Hyvonen et al. [52]
reported that transgenic cows expressing rhLF at 2.9 mg/ml were
not protected from experimental E. coli intra-mammary infection.
Therefore, the effect of rhLF on bacteria mainly depends on its
biologically relevant concentration. Regardless, rhLF indeed has
the potential for use as a bactericide in vitro.
In conclusion, we report here, for the first time, the co-
microinjection with a 150-kb hLF BAC and a marker gene into
donor cells followed by somatic cloning is very efficient in
producing cattle mammary bioreactor, and rhLF was expressed in
the milk reaching a level of 3.4 g/l. Moreover, the biochemical
properties and bioactivities of rhLF were similar to that of natural
hLF. All of the above suggest that the novel procedure of
transgenic cloning developed in this study is convenient and
efficient in generating large animal mammary bioreactors, capable
of great potential for the production of functional heterologous
proteins on a large scale.
Materials and Methods
Preparation of the hLF gene
BAC clones containing the entire hLF genomic sequence
(Genbank accession number: U95626) were obtained by screening
a human BAC library (Genome Systems Inc.). A linearized 150-kb
entire hLF genomic sequence was separated from the BAC clones
(after digested with Not I) by pulse-field-gel-electrophoresis with
CHEF mapper III (Bio-Rad, Hercules, CA) and recovered by
electroelution prior to terminal sequencing for confirmation of
intactness. Procedural detailsare presented inour previous work [24].
Co-microinjection of hLF BAC and a marker gene into
bovine fetal fibroblasts
Tissue biopsies were obtained from the skin of a day 142 bovine
fetus, and fibroblasts from passage 3 to passage 5 were used to
perform microinjection. The hLF BAC DNA (2.5 ng/ml) in TE
buffer (10 mM NaCl, 10 mM Tris-HCl, 1 mM EDTA, pH 8.0)
was mixed with pCMV-EGFP-IRES-NEO (pCEIN)(Clontech Inc.,
Palo Alto, CA) in a molar ratio of 1:3, and this mixture was
microinjected into bovine fetal fibroblast cells. After incubation and
screening for 14 days at 600 mg/ml Geneticin (G418, Life
Technologies, Carlsbad, CA), the resulting cells were collected
and passaged twice in 300 mg/ml G418. PCR was performed to
further screen the positive cells using three pairs of primers covering
the complete hLF gene: FP1 (59 TGCTTTGTTTGTATT-
GAGGGTC 39) and RP1 (59 CCAGGAACAAACTTACGGAG
39, FP2 (59 GATGCTGTGACCCTTGATGG 39) and RP2 (59
CATTCCATCCAGCGGTCC 39), and FP3 (59 TTCCTTCCAC-
CACTGTTGAG 39) and RP3 (59 CAAATACCT-
CTGCCGCTGTT 39). P1, P2 and P3 were designed to amplify
the 59 flanking region, coding sequence of hLF, and 39 flanking
region, respectively.
Electroporation and lipofection
The hLF BAC DNA and pCEIN in TE buffer was co-
introduced into bovine fetal fibroblast cells by electroporation. The
electroporation procedures have been described elsewhere [53]
and was modified in this study. Briefly 5610
6 cells in 400 ml
Hepes-buffered saline were mixed with a final concentration of
2.5 ng/ml hLF BAC DNA and a final concentration of 0.5 ng/ml
pCEIN and electroporated using a DC pulse of 1.2 kV/cm for
1 ms. Twenty-four hours later, G418 was added to select cells
according to the method above. The lipofection was performed
according to instruction of the Lipofectamine
TM 2000 kit
(invitrogen, Carlsbad, CA).
Somatic cell nuclear transfer
Nuclear transfer was preformed as described [53]. Briefly, the
nuclei of transgenic cells were transferred to enucleated oocytes to
produce reconstructed embryos that were then electrically fused by
a BTX 2001 Electro Cell Manipulator (BTX, San Diego, CA).
The reconstructed embryos were activated with 10 mg/ml
cycloheximide and 2.5 mg/ml cytochalasin-D in CR1aa medium
[54]. Day-7 blastocysts were transferred to synchronous recipient
cows with two embryos per recipient. The gestation of recipients
were examined on day 60, 90, and 240. After birth of the calves,
transgenics were identified by PCR and a copy number was
assessed by Southern blot analysis.
Composition analysis of transgenic milk
The intramuscular injection of medroxyprogesterone acetate
(25 mg/kg/day) and estradiol benzoate (7.5 mg/kg/day) to cows
at the age of eight months for seven days was carried out to induce
lactation. Milk was collected for 14 days from the day one of of
lactation. The composition analysis of whole-milk samples was
performed on a MilkoScan 4000 (Foss, Hillero ¨d, Denmark).
Western blotting was carried out with a rabbit polyclonal antibody
Transgenic Cow by Novel Method
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conjugated goat anti-rabbit IgG (Biodesign, Saco, ME).
Two-dimensional electrophoresis
The concentration of total milk protein was measured with a
Bradford Protein Quantity Assay Kit (Biyuntian, Beijing, China).
For the first dimension of gel electrophoresis, defatted milk was
subjected to a linear, immobilized pH gradient on 11-cm-long dry
strips of pH 3–6 or pH 5–8 (Bio-Rad, Hercules, CA). The second
dimension of gel electrophoresis was performed by 15% SDS-
PAGE followed by staining with mass spectrometry–compatible
methods [55]. The digitalized gel images were analyzed by Image
Master Platinum version 6 software (GE Healthcare, Uppsala,
Sweden).
Purification of rhLF from transgenic milk
The rhLF was purified on an A ¨KTA purifier 10 equipped with
a HiLoad 16/10 SP Sepharose HP column (GE Healthcare,
Uppsala, Sweden). Briefly, NaCl (final concentration of 0.4 M)
was added to the transgenic milk prior to removal of milk fat and
casein from the whey by centrifugation at 23,0006g for 60 min.
Then the milk samples were diluted 5-fold in 20 mM sodium
phosphate, 0.4 M NaCl, pH 7.5, filtered with a 0.22 mm filter and
applied to the column. Bound proteins were eluted with a linear
salt gradient of 0.4–1 M NaCl in 20 mM sodium phosphate,
pH 7.5. The flow rate was at 3.0 ml/min, and the absorbance was
measured at 280 nm. The absorbance peaks were integrated with
UNICORN software (GE Healthcare, Uppsala, Sweden). The
rhLF-containing fractions were desalted by ultracentrifugation
using a 50-kDa cutoff ultracentrifuge tube (Centricon, Bedford,
MA), and the retained solution was freeze-dried on Freezone 6
(Labconco, Kansas City, MO).
An ELISA kit (Merck, Darmstadt, Germany) was used to
determine the efficiency of purification. The concentration of
whey (before and after application to the column) and the pooled
rhLF was determined by measuring absorbance at 420 nm on a
Microplate Reader (Bio-Rad, Hercules, CA).
Glycosylation analysis of rhLF
Deglycosylation of rhLF and native hLF with N-glycosidase F
(PNGase F) and Endo H (New England Biolabs, Herts, UK) was
performed as per the manufacturer’s instructions. The rhLF
solution (1 mg/ml) was treated with PNGase F (final concentration
of 5 U/ml) and Endo H (final concentration of 5 U/ml)
respectively, and successively boiled for 5 minutes in non-reducing
SDS-PAGE sample buffer prior to analysis by 7.5% SDS-PAGE.
Analysis of susceptibility to proteolysis
Proteolysis by trypsin (Sigma) was performed according to the
manufacturer’s instructions. Briefly, the trypsin (final concentra-
tion of 0.2 mg/ml) was added to a solution of rhLF (final
concentration of 1 mg/ml) and incubated at 37uC for 15 min. The
reaction was stopped by adding a 10-fold molar excess of Soybean
trypsin inhibiter (Sigma).
Meanwhile, proteolysis by pepsin (Sigma) was carried out
according to the manufacturer’s instructions. The rhLF and native
hLF were dissolved in distilled water at a concentration of 5 mg/
ml with a final pH of ,2.0. Pepsin was then added to each
solution at a final concentration of 0.5 mg/ml and incubated at
37uC for 1 h. The reaction was terminated by adding 0.5 mg/ml
(final concentration) pepstatin A (Sigma). The resulting peptides
were subjected to 15% SDS-PAGE and transferred to a
nitrocellulose membrane as described above.
Iron saturation and desaturation of rhLF
The purified protein was saturated with freshly prepared
FeNTA solution as described [27]. Briefly, the FeNTA solution
(10 mM ferric nitrate, 8.5 mM nitrilotriacetic acid) was adjusted to
pH 7.0 with solid NaHCO3. rhLF was added to the FeNTA
solution to achieve a molar ratio of rhLF to iron of 1:4, and the
solution was incubated at 20uC for 1 h. The resulting iron-
saturated rhLF was dialyzed against 0.15 M NaCl. Spectral
analysis was performed from 260 to 700 nm on a Lincam
spectrophotometer (Lincam, Cambridge, UK).
To measure the potential of rhLF to bind iron under different
conditions, iron-saturated rhLF solutions (5 mg/ml) were dialyzed
for 36 h at room temperature against the following buffers, each of
which contained 0.15 M NaCl: 0.1 M HEPES (pH 7.0); 0.1 M
MES (pH 6.5–5.5); 0.1 M sodium acetate (pH 5.0–3.5); 0.1 M
glycine/HCl (pH 3.0–2.0). Absorbency at 280 nm and 465 nm
was measured on a spectrophotometer. The concentration of iron-
free rhLF was calculated as: (A28021.46(A465/0.058))/1.1 [18].
The proportion of iron-free LF was calculated as the ratio of iron-
free rhLF to total rhLF.
Analysis of rhLF antibacterial activity in vitro
Escherichia coli F107 was obtained from the Conservation Institute
of Chinese Veterinary Microbacteria, Agricultural Ministry of
China. Cells (10
5 CFU/ml in broth agar medium) were incubated
at 37uC with agitation (240 rpm/min) with rhLF solution (final
concentration of 0.5 mg/ml, 2 mg/ml, or 5 mg/ml in broth agar
medium). A negative control was prepared with distilled water in
place of rhLF. The positive control was 2 mg/ml ampicillin solution
inplaceofrhLF.Aliquots(100 ml)ofsamplestakenatdifferenttimes
were measured at 600 nm to detect the growth of bacteria. The
assays were carried out at least three times.
Supporting Information
Figure S1 Localization of the rhLF transgene in chromosomes
of the transgenic calves by fluorescence in situ hybridization. The
arrows indicate the location of rhLF gene on chromosome 15 in
211 (A) and xiang (B).WT is untransgenic cattle.
Found at: doi:10.1371/journal.pone.0003453.s001 (2.44 MB TIF)
Figure S2 I n v e s t i g a t i o no fr h L Fi nt r a n s g e n i cm i l kw i t hM S .A ,
The results of P1(top) and P2 (bottom)analyzed by LCQDeca xp
plus
massspectrometer.Thered sequencesindicatethepeptidesidentified
by mass spectrometer. B, Determination of Mr of rhLf with MALDI-
TOF MS. The Mr of rhLF is 79,494 Dalton. C, Identification of
different proteins, A (left) and B (right), in two dimensional
electrophoresis with MALDI-TOF MS. Match sequences of A and
B were beta-lactoglobulin variant a and beta-lactoglobulin variant b
of cattle, Sequence coverage of beta-lactoglobulin variant a and beta-
lactoglobulin variant b were 44% and 50% respectively.
Found at: doi:10.1371/journal.pone.0003453.s002 (2.88 MB TIF)
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